Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis

Metabolism: Clinical and Experimental
D RobertW Riesen

Abstract

The role of the remmant kidney tissue in uremic patients undergoing hemodialysis treatment has rarely been considered to influence the changes in lipoprotein and lipid metabolism. Twenty hemodialyzed patients with remnant kidneys and 11 anephric patients were studied to examine whether the presence or the absence of remnant kidney leads to qualitative or quantitative changes of the lipids and lipoproteins. Anephric patients showed a significantly higher triglyceride level, 3.66 +/- 0.49 (SEM) mmol/L v 2.34 +/- 0.09 mmol/L in patients with remnant kidneys (P less than .01), higher very-low-density lipoprotein (VLDL) triglycerides, 1.24 +/- 0.30 mmol/L v 0.69 +/- 0.09 (P less than .04), and higher HDL-triglycerides, 1.22 +/- 0.29 mmol/L v 0.66 +/- 0.09 mmol/L (P less than .04). APO-AI was significantly decreased in anephric patients, 95.2 +/- 13.3 mg/dL v 129.7 +/- 6.02 mg/dL in patients with remnant kidneys (P less than .01). APO-B was similar in both groups. All APO-C and APO-E were significantly lower in anephric patients, APO-CI 6.13 +/- 0.87 mg/dL v 8.47 +/- 0.42 mg/dL in patients with remnant kidneys (P less than .01), APO CII 1.00 +/- 0.01 mg/dL v 10.0 +/- 0.01 mg/dL (P less than .0001), APO-CIII 10.12 +/- 1.43 mg/dL v 26....Continue Reading

References

Mar 1, 1976·Metabolism: Clinical and Experimental·T K SinhaN H Bell
Jan 1, 1977·Kidney International·M L SanfelippoG M Reaven
Jun 23, 1977·The New England Journal of Medicine·J D Bagdade, J J Albers
Aug 1, 1977·Metabolism: Clinical and Experimental·J D BrunzellD J Sherrard
Dec 22, 1977·The New England Journal of Medicine·R MordasiniH Greten
Apr 1, 1978·Metabolism: Clinical and Experimental·J J AlbersW R Hazzard
Dec 28, 1978·The New England Journal of Medicine·D W CoxJ A Little
Apr 2, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·J M FeltsG Childress
Apr 2, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·I StapransB Zacherle
Oct 1, 1979·Metabolism: Clinical and Experimental·G SchonfeldJ Witztum
Dec 1, 1978·The Journal of Clinical Endocrinology and Metabolism·A GoldbergJ D Brunzell
Jun 8, 1978·The New England Journal of Medicine·W C BreckenridgeM Poapst
Jan 15, 1986·Clinica Chimica Acta; International Journal of Clinical Chemistry·W F RiesenR Mordasini
Oct 1, 1986·Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Für Klinische Chemie Und Klinische Biochemie·W F Riesen, E Sturzenegger
Feb 1, 1985·The Journal of Clinical Investigation·M L McCalebD H Lockwood
Feb 1, 1985·The Journal of Clinical Investigation·C S WangP Alaupovic
Jul 25, 1968·The New England Journal of Medicine·J D BagdadeE L Bierman
Oct 1, 1984·Kidney International·D R PetersonP A Moore
Jul 1, 1980·The American Journal of Clinical Nutrition·R A DeFronzo, A Alvestrand
May 1, 1981·Kidney International·M K ChanJ F Moorhead
Aug 5, 1982·The New England Journal of Medicine·P J NestelM H Tan
May 1, 1980·European Journal of Biochemistry·G Bengtsson, T Olivecrona

❮ Previous
Next ❯

Citations

Jan 1, 1991·Progress in Lipid Research·P O Attman, P Alaupovic
Dec 1, 1990·Baillière's Clinical Endocrinology and Metabolism·C D Short, P N Durrington
Aug 1, 1993·Journal of Internal Medicine·S ZambonE Manzato
Jun 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·P O AttmanP Alaupovic
Mar 24, 2004·Journal of Ethnopharmacology·Gustavo F Scarpa
Sep 1, 1991·Equine Veterinary Journal·J Shepherd

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.